EXAMINATION OF PERCUTANEOUS APPLICATION IN A 26-WEEK CARCINOGENICITY TEST IN CB6F1-TG rasH2 MICE

スポンサーリンク

概要

• 論文の詳細を見る

• We examined the possibility of expanding applications of rasH2 mice, which are genetically manipulated mice for short-term carcinogenicity tests, to percutaneous application. A 26-week short-term carcinogenicity study was performed on a total of 300 mice including 75 male and female rasH2 mice each, and 75 male and female non-Tg mice each from the same litter as the rasH2 mice divided into untreated group, an ethanol group, a white Vaseline group, an acetone group, and a phorbol 12-myristate 13-acetate (TPA) group. Only shaving of dorsal skin was performed on the untreated mice. As a positive control, TPA was administered percutaneously at a dose of 2.5μg/kg and 3 times/week for 26 weeks based on the protocol for Tg. AC mice in the ILSI/HESI international validation study. In the ethanol, white Vaseline, and acetone groups, no tumorous changes were observed on the skin at the administration site. In the TPA group, nodular changes at the administration site were observed from seven weeks after the start of administration in rasH2 mice, and the incidence in males and females was 50.0% (7/14) and 53.3% (8/15), respectively. In a pathological examination, nodules in 21.4% (3/14) of males and 46.7% (7/15) of females were diagnosed as skin papilloma or keratoacanthoma, and the rest as squamous cell hyperplasia. In the non-Tg mice, no nodules or tumorigenic changes were observed at the administration site. These findings show that percutaneous application in rasH2 mice is possible in 26-week carcinogenicity tests.

• 2007-10-15

著者

• Hattori Yuji

  Central Institute For Experimental Animals

• Suzuki Shuzou

  Central Institute For Experimental Animals

• Machida Kazuhiko

  Central Institute for Experimental Animals

• Urano Koji

  Central Institute for Experimental Animals

• Usui Toshimi

  Central Institute for Experimental Animals

• Urano Kouji

  Central Institute For Experimental Animals

• Machida Kazuhiko

  The Department Of Pathology Nippon Experimental Medical Research Institute Co. Ltd

• Suzuki Shuzo

  Central Institute For Experimental Animals

• EGUCHI Natsuko

  Central Institute for Experimental Animals

• SAWA Nobuko

  Central Institute for Experimental Animals

• KIKUCHI Koji

  JAC, Inc.

• Kikuchi Kouji

  Jac Inc.

関連論文

• Carcinogenic comparative study on rasH2 mice produced by two breeding facilities
• "C-7 A Rapid Carcinogenicity Test in Transgenic Mice Carrying Human c-Ha-ras Gene.
• EXAMINATION OF PERCUTANEOUS APPLICATION IN A 26-WEEK CARCINOGENICITY TEST IN CB6F1-TG rasH2 MICE
• A rapid carcinogenicity testing system using transgenic mice harboring human prototype c-Ha-ras gene
• Induction of Drug Metabolism-Related Enzymes by Methylcholanthrene and Phenobarbital in Transgenic Mice Carrying Human Prototype c-Ha-ras Gene and Their Wild Type Littermates
• Leukocyte Differential Analysis in Multiple Laboratory Species by a Laser Multi-Angle Polarized Light Scattering Separation Method
• Use of IC tags in short-term carcinogenicity studies on CB6F1-TgrasH2 mice(Carcinogenicity, Proceedings of the 32nd Annual Meeting)
• P8-31 Effect of vehicles for a dermal carcinogenicity testing of CB6F1-TgrasH2 mice(STATISTICAL AND TEST METHODS/LOCAL STIMURATION)(GENERAL SESSION BY POSTER PRESENTATION)(Proceedings of the 31st Annual Meeting)
• P6-41 Comparative study on the carcinogenicity of phenolphthalein in rasH2 and p53 knockout mice(DRUG METABOLISM/CARCINOGENICITY)(GENERAL SESSION BY POSTER PRESENTATION)(Proceedings of the 31st Annual Meeting)
• Influence of the administration route and the vehicle on CB6F1-TgrasH2 mice (CARCINOGENICITY) (GENERAL SESSION BY POSTER PRESENTATION) (Proceedings of the 30th Annual Meeting)
• Background data of human prototype c-Ha-ras transgenic (CB6Fl-TgrasH2) mice (CARCINOGENICITY) (GENERAL SESSION BY POSTER PRESENTATION) (Proceedings of the 30th Annual Meeting)
• Biological characteristics of gene-manipulated mice for carcinogenicity test (CARCINOGENICITY) (GENERAL SESSION BY POSTER PRESENTATION) (Proceedings of the 30th Annual Meeting)
• USE OF IC TAGS IN SHORT-TERM CARCINOGENICITY STUDY ON CB6F1 TGrasH2 MICE
• P-44 Some Consideration to the Significance of Serum Immunogiobulin Levels in the Immunotoxicy Testing(Proceedings of the 27th Annual Meeting)
• 22C-10-5 Differences in toxic changes between CB6F1-Tg-rasH2 mice and their nontransgenic littermates given cyclophosphamide by gavage weekly for 5 or 26 weeks (2) Immunotoxicity.
• 21D-03-1 Differences in toxic changes between CB6F1-Tg-rasH2 mice and their nontransgenic littermates given cyclophosphamide by gavage weekly for 5 or 26 weeks (1) General toxicity.
• P-46 Differences in immunotoxic changes between CB6F1-Tg-rasH2 mice and their nontransgenic littermates given cyclophosphamide by gavage weekly for 5 weeks.(Proceedings of the 27th Annual Meeting)
• Report 1 : TESTING FOR CARCINOGENICITY OF PHARMACEUTICALS : S1, A ; Conditions which require carcinogenicity studies for pharmaceuticals S1, B ; Use of two rodent species S1, C ; Dose selection for carcinogenicity studies of pharmaceuticals (CA
• Acute neurotoxicity study in rats given a single oral administration of Trimethyltin chloride and Acrylamide.(GENERAL SESSION BY POSTER PRESENTATION)(NERVOUS SYSTEM)
• The analysis of locomotor activity of male and female rats in functional observation buttery (FOB) in neurotoxicity study.(GENERAL SESSION BY POSTER PRESENTATION)(NERVOUS SYSTEM)
• Higher susceptibility of NOG mice to xenotransplanted tumors
• Carcinogenic comparative study on rasH2 mice produced by two breeding facilities

もっと見る 閉じる

スポンサーリンク